Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 10/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 10/20 | 0.47 |
| ▸ | ADH5 | P11766 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.39 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.39 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.39 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26919872 | 1.00 | SRD5A2 (0.47) | SRD5A2AKR1C3AKR1C2ADH5S1PR1 | |
| SCHEMBL26919869 | 1.00 | SRD5A2 (0.47) | SRD5A2AKR1C3AKR1C2ADH5S1PR1 | |
| SCHEMBL30991461 | 0.89 | SRD5A2 (0.46) | SRD5A2AKR1C3AKR1C2ADH5S1PR1 | |
| SCHEMBL26919977 | 0.80 | AKR1C3 (0.45) | SRD5A2AKR1C3AKR1C2ADH5S1PR1 | |
| SCHEMBL26919975 | 0.80 | AKR1C3 (0.45) | SRD5A2AKR1C3AKR1C2ADH5S1PR1 | |
| SCHEMBL20705294 | 0.79 | HDAC8 (0.50) | KIF11 | |
| SCHEMBL20705293 | 0.79 | HDAC8 (0.50) | KIF11 | |
| SCHEMBL30991476 | 0.79 | AKR1C3 (0.50) | SRD5A2AKR1C3AKR1C2ADH5S1PR1 | |
| SCHEMBL26946396 | 0.78 | AKR1C3 (0.46) | SRD5A2AKR1C3AKR1C2ADH5S1PR1 | |
| SCHEMBL26936362 | 0.78 | S1PR1 (0.42) | SRD5A2AKR1C3AKR1C2ADH5S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023237651-A1 | METHOD FOR THE PREPARATION OF A 3,6-DIHYDRO-2H-1,3,4-OXADIAZIN-2-ONE | BAYER AKTIENGESELLSCHAFT (DE) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023237651-A1 | METHOD FOR THE PREPARATION OF A 3,6-DIHYDRO-2H-1,3,4-OXADIAZIN-2-ONE | BAYER AKTIENGESELLSCHAFT (DE) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023237656-A1 | CRYSTALLINE FORMS OF (6S)-5-[4'-FLUORO-2-(TRIFLUOROMETHYL)BIPHENYL-4-YL]-6-METHYL-3,6-DIHYDRO-2H-1,3,4-OXADIAZIN-2-ONE | BAYER AKTIENGESELLSCHAFT (DE) | 2023-12-14 | — | — | WO | disclosed |
| EP-4289829-A1 | CRYSTALLINE FORMS OF (6S)-5-[4'-FLUORO-2-(TRIFLUOROMETHYL)BIPHENYL-4-YL]-6-METHYL-3,6-DIHYDRO- 2H-1,3,4-OXADIAZIN-2-ONE | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289828-A1 | METHOD FOR THE PREPARATION OF A 3,6-DIHYDRO-2H-1,3,4-OXADIAZIN-2-ONE | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289829-A1 | CRYSTALLINE FORMS OF (6S)-5-[4'-FLUORO-2-(TRIFLUOROMETHYL)BIPHENYL-4-YL]-6-METHYL-3,6-DIHYDRO- 2H-1,3,4-OXADIAZIN-2-ONE | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289828-A1 | METHOD FOR THE PREPARATION OF A 3,6-DIHYDRO-2H-1,3,4-OXADIAZIN-2-ONE | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |